Figure 1: No rebound is observed in secukinumab-treated patients within 8 weeks after dosing.




Figure 2: CAIN457A2211 Study Design




Figure 3: PASI75 response rates in study CAIN457A2211 during the 12 week induction phase, following different treatment regimens of 150 mg s.c. secukinumab,





Figure 4: Study A2211 PASI 75 achievement by patient visit (subgroup of subjects randomized to the maintenance period)






Figure 5: Observed cumulative probability to experience "Start of Relapse" in "individualized treatment" maintenance in study CAIN457A2211.

Figure 6: CAIN457A2220 Study Design





Figure 7: Results from study CAIN457A2220 (12 weeks)

Figure 8: Simulated i.v. and s.c. exposures for different secukinumab regimens



In order (top to bottom)

i.v. 3 x 10 mg/kg

s.c. 300 mg weekly for 1st month, then monthly

s.c. 150 mg weekly for 1st month, then monthly

s.c. 75 mg weekly for 1st month, then monthly

i.v. 1 x 10 mg/kg

s.c. "early"




Figure 9: Simulated PASI 75 induction and maintenance response rates for phase III doses

Figure 10: Simulated PASI 75 response rates for different fixed treatment intervals




Figure 11: CAIN457A2304 Study design

